Abbott Laboratories (ABT): Price and Financial Metrics

Abbott Laboratories (ABT): $105.27

0.57 (+0.54%)

POWR Rating

Component Grades














  • Stability is the dimension where ABT ranks best; there it ranks ahead of 89.07% of US stocks.
  • The strongest trend for ABT is in Quality, which has been heading up over the past 179 days.
  • ABT ranks lowest in Momentum; there it ranks in the 26th percentile.

ABT Stock Summary

  • ABBOTT LABORATORIES's market capitalization of $179,867,779,804 is ahead of 99.13% of US-listed equities.
  • ABBOTT LABORATORIES's stock had its IPO on January 1, 1986, making it an older stock than 93.28% of US equities in our set.
  • In terms of volatility of its share price, ABT is more volatile than just 23.35% of stocks we're observing.
  • Stocks that are quantitatively similar to ABT, based on their financial statements, market capitalization, and price volatility, are DHR, TMO, UPS, DIS, and VZ.
  • ABT's SEC filings can be seen here. And to visit ABBOTT LABORATORIES's official web site, go to

ABT Valuation Summary

  • ABT's price/sales ratio is 4; this is 81.82% higher than that of the median Healthcare stock.
  • Over the past 243 months, ABT's price/earnings ratio has gone down 0.5.

Below are key valuation metrics over time for ABT.

Stock Date P/S P/B P/E EV/EBIT
ABT 2022-09-01 4.0 5.0 21.5 18.1
ABT 2022-08-31 3.9 4.9 21.0 17.7
ABT 2022-08-30 3.9 4.9 20.9 17.7
ABT 2022-08-29 3.9 4.9 20.8 17.6
ABT 2022-08-26 3.9 4.9 20.9 17.6
ABT 2022-08-25 4.1 5.1 21.7 18.3

ABT Growth Metrics

    Its year over year price growth rate is now at -5.13%.
  • Its 5 year price growth rate is now at 140.44%.
  • Its 2 year net cashflow from operations growth rate is now at 62.26%.
ABT's revenue has moved up $8,210,000,000 over the prior 15 months.

The table below shows ABT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 45,548 10,243 8,554
2022-03-31 44,514 9,961 7,725
2021-12-31 43,075 10,533 7,071
2021-09-30 42,308 11,264 7,244
2021-06-30 40,233 10,629 6,376
2021-03-31 37,338 9,823 5,724

ABT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABT has a Quality Grade of B, ranking ahead of 77.76% of graded US stocks.
  • ABT's asset turnover comes in at 0.559 -- ranking 70th of 680 Pharmaceutical Products stocks.
  • DVAX, RARE, and CORT are the stocks whose asset turnover ratios are most correlated with ABT.

The table below shows ABT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.559 0.557 0.230
2021-03-31 0.527 0.568 0.205
2020-12-31 0.499 0.566 0.166
2020-09-30 0.473 0.567 0.135
2020-06-30 0.462 0.576 0.128
2020-03-31 0.473 0.584 0.147

ABT Price Target

For more insight on analysts targets of ABT, see our ABT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $132.05 Average Broker Recommendation 1.48 (Moderate Buy)

ABT Stock Price Chart Interactive Chart >

Price chart for ABT

ABT Price/Volume Stats

Current price $105.27 52-week high $142.60
Prev. close $104.70 52-week low $101.21
Day low $103.59 Volume 1,205,213
Day high $105.36 Avg. volume 5,426,712
50-day MA $107.95 Dividend yield 1.8%
200-day MA $118.21 Market Cap 184.35B

Abbott Laboratories (ABT) Company Bio

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. (Source:Wikipedia)

ABT Latest News Stream

Event/Time News Detail
Loading, please wait...

ABT Latest Social Stream

Loading social stream, please wait...

View Full ABT Social Stream

Latest ABT News From Around the Web

Below are the latest news stories about ABBOTT LABORATORIES that investors may wish to consider to help them evaluate ABT as an investment opportunity.

3 Dividend Stocks to Buy in September for Passive Income Generation

Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. Here's how they could provide ever-increasing dividend payments to your brokerage account. Shares of Abbott Laboratories (NYSE: ABT) have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests.

Yahoo | September 1, 2022

Abbott (ABT) Gains As Market Dips: What You Should Know

In the latest trading session, Abbott (ABT) closed at $102.65, marking a +0.44% move from the previous day.

Yahoo | August 31, 2022

Top 10 Stock Picks of Robert B. Gillam’s McKinley Capital Management

This article discusses the top ten stock picks of Robert B. Gillam’s McKinley Capital Management at the end of the second quarter. You can skip our detailed analysis of the hedge fund’s performance and its investment strategy, and go directly to read Top 5 Stock Picks of Robert B. Gillam’s McKinley Capital Management. Bob Gillam, […]

Yahoo | August 30, 2022

New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

Abbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease. The data are from the MOMENTUM 3 trial, the world's largest randomized clinical trial to assess long-term outcomes in people receiving a left ventricular assist device (known as an LVAD, or heart pump) to treat advanced heart failure. The data were p

Yahoo | August 29, 2022

Abbott restarts Similac infant formula production at Michigan facility

Abbott, the biggest U.S. supplier of baby formula, in February recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products that originated there. The plant shutdown and subsequent product recall deepened a supply shortage in a nation where less than half of babies are exclusively breast-fed through their first three months, according to federal data from 2020.

Yahoo | August 27, 2022

Read More 'ABT' Stories Here

ABT Price Returns

1-mo -2.45%
3-mo -3.55%
6-mo -6.89%
1-year -17.14%
3-year 31.00%
5-year 119.75%
YTD -24.30%
2021 30.53%
2020 28.04%
2019 22.08%
2018 29.06%
2017 52.03%

ABT Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABT Dividend History

Continue Researching ABT

Here are a few links from around the web to help you further your research on Abbott Laboratories's stock as an investment opportunity:

Abbott Laboratories (ABT) Stock Price | Nasdaq
Abbott Laboratories (ABT) Stock Quote, History and News - Yahoo Finance
Abbott Laboratories (ABT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6872 seconds.